Company Description
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.
The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.
In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension.
The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 593 |
| CEO | Han Ying |
Contact Details
Address: 12770 High Bluff Drive, Suite 150 San Diego, California 92130 United States | |
| Phone | 619-949-3681 |
| Website | gyretx.com |
Stock Details
| Ticker Symbol | GYRE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| ISIN Number | US4037831033 |
| Employer ID | 56-2020050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Han Ying Ph.D. | Chief Executive Officer and Director |
| Songjiang Ma | President and Director |
| Ruoyu Chen | Chief Financial Officer |
| Weiguo Ye | Chief Operating Officer |
| Seline E. Miller CPA | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 27, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 424B5 | Filing |
| Nov 22, 2024 | EFFECT | Notice of Effectiveness |
| Nov 14, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Sep 6, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 6, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |